EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 126 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $292,171 | -65.1% | 18,527 | -56.9% | 0.00% | -100.0% |
| Q2 2023 | $836,289 | +51.6% | 43,019 | +121.2% | 0.00% | 0.0% |
| Q1 2023 | $551,683 | -24.7% | 19,446 | -22.4% | 0.00% | 0.0% |
| Q4 2022 | $732,212 | -99.9% | 25,050 | +7.5% | 0.00% | 0.0% |
| Q3 2022 | $615,480,000 | +338.4% | 23,296 | +637.2% | 0.00% | – |
| Q2 2022 | $140,399,000 | -23.6% | 3,160 | -14.9% | 0.00% | – |
| Q1 2022 | $183,707,000 | -43.6% | 3,712 | -42.0% | 0.00% | – |
| Q4 2021 | $325,735,000 | -50.5% | 6,397 | -45.8% | 0.00% | -100.0% |
| Q3 2021 | $657,814,000 | +253.2% | 11,793 | +171.0% | 0.00% | – |
| Q2 2021 | $186,223,000 | +99.2% | 4,351 | +94.2% | 0.00% | – |
| Q1 2021 | $93,498,000 | +8.4% | 2,240 | +21.0% | 0.00% | – |
| Q4 2020 | $86,248,000 | -32.4% | 1,852 | -38.3% | 0.00% | – |
| Q3 2020 | $127,525,000 | +48.2% | 3,002 | +67.4% | 0.00% | – |
| Q2 2020 | $86,028,000 | -91.5% | 1,793 | -91.8% | 0.00% | -100.0% |
| Q1 2020 | $1,011,356,000 | +620.3% | 21,986 | +840.8% | 0.00% | – |
| Q4 2019 | $140,407,000 | -87.3% | 2,337 | -88.1% | 0.00% | -100.0% |
| Q3 2019 | $1,109,677,000 | +3.9% | 19,616 | +2.2% | 0.00% | 0.0% |
| Q2 2019 | $1,068,221,000 | +713.1% | 19,185 | +637.3% | 0.00% | – |
| Q1 2019 | $131,375,000 | +709.1% | 2,602 | +545.7% | 0.00% | – |
| Q4 2018 | $16,237,000 | -92.4% | 403 | -86.9% | 0.00% | – |
| Q3 2018 | $212,912,000 | -8.4% | 3,071 | 0.0% | 0.00% | – |
| Q2 2018 | $232,352,000 | -59.9% | 3,071 | -72.0% | 0.00% | -100.0% |
| Q1 2018 | $578,852,000 | -6.3% | 10,986 | -5.0% | 0.00% | 0.0% |
| Q4 2017 | $617,535,000 | -12.5% | 11,560 | -2.3% | 0.00% | -50.0% |
| Q3 2017 | $705,839,000 | +264.3% | 11,835 | +381.9% | 0.00% | +100.0% |
| Q2 2017 | $193,754,000 | +50.9% | 2,456 | +58.7% | 0.00% | – |
| Q1 2017 | $128,391,000 | +20.2% | 1,548 | +15.0% | 0.00% | -100.0% |
| Q4 2016 | $106,792,000 | +27.9% | 1,346 | +12.8% | 0.00% | – |
| Q3 2016 | $83,510,000 | +503.0% | 1,193 | +234.2% | 0.00% | – |
| Q2 2016 | $13,848,000 | -92.7% | 357 | -83.3% | 0.00% | – |
| Q4 2015 | $189,044,000 | +50.0% | 2,132 | +25.3% | 0.00% | – |
| Q3 2015 | $125,999,000 | +118.5% | 1,702 | +138.7% | 0.00% | – |
| Q2 2015 | $57,653,000 | +4199.3% | 713 | +572.6% | 0.00% | – |
| Q3 2014 | $1,341,000 | -73.5% | 106 | -70.0% | 0.00% | – |
| Q2 2014 | $5,058,000 | – | 353 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |